Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
Sponsor: Climb Bio, Inc.
Summary
The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Injections of Budoprutug (TNT119) in Normal Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2025-08-11
Completion Date
2026-06
Last Updated
2026-03-13
Healthy Volunteers
Yes
Conditions
Interventions
Budoprutug
Subcutaneous or IV administration
Placebo
Placebo comparator
Locations (1)
Nucleus Network Brisbane
Brisbane, Australia